OTC: TLPPF - Telix Pharmaceuticals Limited

Rentabilität für sechs Monate: +65.38%
Dividendenrendite: 0.00%
Sektor: Healthcare

Aktionsplan Telix Pharmaceuticals Limited

Erweiterter Zeitplan Einfaches Diagramm
Financial Markets by TradingView

Über das Unternehmen Telix Pharmaceuticals Limited

Telix Pharmaceuticals Limited, a radiopharmaceutical company, develops molecularly targeted radiation (MTR) products for cancer and rare diseases in Australia, Belgium, Japan, Switzerland, and the United States. The company focuses on developing diagnostic and therapeutic products using MTR.

weitere details
Its lead products include TLX591-CDx for the diagnosis and treatment of metastatic castrate-resistant prostate cancer; TLX250-CDx that is in Phase III clinical trials for the diagnosis and treatment of renal (kidney) cancer; TLX101-CDx for the diagnosis and treatment of glioblastoma (brain cancer); TLX66-CDx to treat bone marrow conditioning and rare diseases; TLX250, which is in Phase II clinical trials for the diagnosis and treatment of kidney cancer; TLX591, which is in Phase III clinical trials for the diagnosis and treatment of metastatic castrate-resistant prostate cancer; TLX101 that is in Phase I/II clinical trials for the treatment of glioblastoma (brain cancer); and TLX66, which is in Phase I/IIa clinical trials for the treatment of bone marrow conditioning and rare diseases. The company also develops TLX592, a prostate cancer therapy candidate for targeted alpha therapy; TLX591-Sx, a positron emission tomography (PET) tracer that delivers PET and fluorescent (optical) imaging; and TLX599-CDx, an investigational prostate cancer imaging agent that uses single photon emission computed tomography. It has a strategic license and commercial partnership with Mauna Kea Technologies and Lightpoint Medical to develop advanced image and radio-guided surgical technologies. The company was founded in 2015 and is headquartered in North Melbourne, Australia.
Zur Vergleichsliste hinzufügen
Auf die Beobachtungsliste
Zum Portfolio hinzufügen
Preishinweis hinzufügen

Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://telixpharma.com
Цена ао 19.25
Preisänderung pro Tag: 0% (19.151)
Preisänderung pro Woche: +1.33% (18.9)
Preisänderung pro Monat: +5.23% (18.2)
Preisänderung über 3 Monate: +23.55% (15.5)
Preisänderung über sechs Monate: +65.38% (11.58)
Preisänderung pro Jahr: +132.42% (8.24)
Preisänderung über 3 Jahre: +447.17% (3.5)
Preisänderung über 5 Jahre: +1 894.9% (0.96)
Preisänderung über 10 Jahre: 0% (19.151)
Preisänderung seit Jahresbeginn: +20.45% (15.9)
Alle Parameter

Unterschätzung

Name Bedeutung Grad
P/S 10.34 1
P/BV 14.26 1
P/E 162.28 1
EV/EBITDA 51.61 1
Gesamt: 2.13

Effizienz

Name Bedeutung Grad
ROA, % 4.75 1
ROE, % 12.69 4
Gesamt: 2.17

Dividenden

Name Bedeutung Grad
Div yield, % 0 0
DSI 0 0
Gesamt: 0

Pflicht

Name Bedeutung Grad
Debt/EBITDA 9 0
Gesamt: 6

Wachstumsimpuls

Name Bedeutung Grad
Rentabilität Revenue, % 12653.85 10
Rentabilität Ebitda, % -165.18 0
Rentabilität EPS, % -165.09 0
Gesamt: 2
Weitere Details

Institutionen Volumen Aktie, %
Vanguard International Stock Index-Total Intl Stock Indx 2270925 0.7
iShares Core MSCI EAFE ETF 1376002 0.42
Vanguard Tax Managed Fund-Vanguard Developed Markets Index Fund 1343237 0.41
College Retirement Equities Fund-Stock Account 937783 0.29
iShares MSCI EAFE Small Cap ETF 923323 0.28
TIAA-CREF Funds-Quant International Small Cap Equity Fund 706384 0.22
Vanguard Intl Equity Index Fds-FTSE All World ex U.S.Small Cap Index 619774 0.19
SPDR Portfolio Developed World ex-US ETF 468831 0.14
Schwab Strategic Tr-Schwab International Small Cap Equity ETF 323859 0.1
iShares Core MSCI Total International Stock ETF 312675 0.1



Aufsicht Berufsbezeichnung Zahlung Geburtsjahr
Mr. Darren Smith B.Bus., FCPA, M.B.A. Group Chief Financial Officer 379.52k 1965 (60 Jahre)
Dr. Andreas Kluge M.D., Ph.D. Chief Medical Advisor & Non-Executive Director 28.57k 1965 (60 Jahre)
Mr. Richard Valeix M.B.A. Chief Executive Officer of Telix Therapeutics 424.25k 1975 (50 Jahre)
Mr. Craig Ulrick Chief Information Officer N/A
Ms. Kyahn Williamson B.A. Senior Vice President of Corporate Communications & Investor Relations N/A
Ms. Melanie Farris (AGIA, ACG, ACIS) BComn, B.Com., GradDip, M.A.I.C. Senior Vice President of Global Governance, Risk & Compliance N/A
Mr. Darren Patti Group Chief Operating Officer N/A 1972 (53 Jahr)
Dr. David N. Cade M.B.A., M.D., MBBS Group Chief Medical Officer N/A 1969 (56 Jahre)
Dr. Christian P. Behrenbruch BEng(Hons), DPhil(Oxon), GAICD, J.D., M.B.A., MBA Co-Founder, MD, Group CEO & Executive Director 1976 (49 Jahre)
Dr. Michael Wheatcroft B.Sc., BSc(Hons), Ph.D., Ph.D., (Cantab) Chief Scientist

Adresse: Australia, North Melbourne. VIC, 55 Flemington Road - in Google Maps öffnen, Öffnen Sie Yandex-Karten
Webseite: https://telixpharma.com